Introduction
Patient-derived induced pluripotent stem cells (iPSCs) offer valuable approaches to model human blood disorders 1, 2, 3, 4 . However different wild type iPSC lines vary greatly in hematopoietic potential, complicating the ability to ascertain phenotypic abnormalities in mutant lines by comparative studies 5, 6 . Reasons for this observed variability between normal iPSC lines are unknown, but may involve genetic and/or epigenetic differences. These differences may derive from donor specific properties related to the cell type of origin or baseline genotype. Additionally, dissimilar reprogramming strategies 7 and the persistence 8 or reactivation of reprogramming transgenes 5 may alter the properties of iPSCs. Finally, acquired chromosomal aberrations, including point mutations or copy number variations (CNVs) in iPSCs with apparently normal karyotypes could cause phenotype variation 9, 10 . The utility of iPSCs for modeling hematopoietic disorders hinges on demonstrating their consistent and reproducible features, including in vitro developmental capacity. In this report, we show that iPSC lines generated from the same individual exhibit gene expression signatures and hematopoietic development that are more similar to each other than those of iPSCs generated from different individuals. Our findings provide a new set of standardized iPSC reference lines for future studies, begin to unravel the mechanisms for variation among different iPSC clones and offer important lessons regarding the use of iPSCs for modeling human disease.
Methods
Normal fibroblasts from Coriell Institute Cell Repository (GM00969 and GM05565) and Children's Hospital of Philadelphia IACUC and Boston University IRB committees, and this study was conducted in accordance with the Declaration of Helsinki.
Results and Discussion
We sought to create panels of "isogenic" reference iPSCs consisting of multiple clones from the same sources and begin to explore the mechanisms associated with clonal variation in hematopoietic development. We used the STEMCCA lentiviral vector to reprogram human fibroblast lines from three unrelated normal subjects 11 . Three different iPSC lines from each individual were characterized (Supplemental Figure 1) . Southern blot analysis identified lines containing a single lentiviral integration site and the reprogramming gene cassettes were removed subsequently by CRE recombinase-mediated excision. All lines analyzed further displayed normal ESC-like morphology, normal karyotype, expression of endogenous pluripotency markers and the capacity to form cells representing three germ layers in teratomas. All of these standard criteria for pluripotency were maintained after more than 20 cell passages.
We performed transcriptome analysis from cells grown under identical conditions. lines and found that the 2.2 and 2.3 clones were more similar to each other than to 2.1, in agreement with PCA. We identified 50 genes that were differentially regulated (>1.5 fold) between these groups ( Figure 1B (ii) and Supplemental Table 1 ). Differences in two of these transcripts, DPPA3 and ID3, were validated by qRT-PCR ( Figure 1B (ii) and Supplemental Table 1 ). We observed little difference in the transcriptome profiles between human ESCs and iPSCs, in agreement with published studies 12, 13 .
Copy number variation (CNV), reflected by gain or loss of chromosomal DNA segments, can occur in iPSCs and contribute to their phenotypic variation 9, 10, 14 . The CNVs For personal use only. on October 24, 2017. by guest www.bloodjournal.org From that differ between the original fibroblast lines and their iPSC progeny are described in Figure   1C and Supplemental Table 2 . Three lines (BMC1, BMC2, CHOPWT2.2) had no detectable reprogramming associated CNVs. The BMC3 line and the three CHOPWT1 lines had CNVs affecting 1 or 2 genes. CHOPWT2.3 iPSCs had 2 larger duplications affecting 21 genes, while CHOPWT2.1 had a large deletion and three duplications (>200KB) affecting 48 genes.
Considering that growth promoting mutations can be selected for in culture, we examined the expansion rate of the iPSC lines. All iPSC lines expanded at similar rates, except for CHOPWT2.1, which grew approximately 2-fold faster ( Figure 1D ). This could reflect increased expression of genes associated with multiple CNVs present including ID1 or BCL2L1 (BCLX) 9, 10 , which were up regulated in the CHOPWT2.1 line ( Figure 1B (ii) ). These data are consistent with prior work suggesting that a chromosome 20 minimal amplicon involving region q11.1-q11.21, which is acquired in CHOPWT2.1, can confer a growth advantage to ESCs and iPSCs. (Figures 2A (iii) , 2B and Supplementary 2C). The CHOPWT2.1 line also produced larger megakaryocyte colonies, reflecting increased proliferative capacity ( Figure 2C) . In liquid cultures, CHOPWT2.1 generated increased absolute numbers (~3-fold) and proportion (~2-fold) of CD41 + CD42 + megakaryocytes compared to the two other iPSC clones from the same fibroblast source ( Figure 2D (i-ii) ). Thus, the CHOPWT2.1 iPSC line exhibits distinct differences from the eight other lines, including an altered transcriptome, increased expansion rate and enhanced production of multi-lineage and megakaryocytic hematopoietic progenitors. It is possible that these differences result from altered gene dosages associated with CNVs. For example, the anti-apoptotic gene BCL2L1/BCLX, which is amplified in CHOPWT2.1 and previously implicated in human ESC expansion, has also been shown to promote megakaryopoiesis [16] [17] [18] . However, selected genes within the CNV regions (FYN, HSBP1, TBL1XR1, CDH12, ID1, and BCL2L1/BCLX) were expressed at similar levels in megakaryocytes generated from all WT2 clones (data not shown). Thus, we cannot directly implicate these genes in the enhanced expansion of megakaryocytes produced by clone 
